LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hereditary Cancer Test Identifies Deleterious Mutations in Endometrial Cancer

By LabMedica International staff writers
Posted on 05 Apr 2016
Print article
Image: Schematics of the three biomarker myChoice homologous recombination deficiency (HRD) assay (Photo courtesy of Myriad Genetics).
Image: Schematics of the three biomarker myChoice homologous recombination deficiency (HRD) assay (Photo courtesy of Myriad Genetics).
Two recent studies have shown that a Hereditary Cancer test can identify deleterious mutations in patients with endometrial cancer and additionally, showed the superior ability of the combined three biomarker test to predict survival in patients with platinum treated ovarian cancer.

One study carried out by scientists from MD Anderson Cancer Center (Houston, TX, USA) evaluated the prevalence of cancer predisposition gene mutations in 381 endometrial cancer patients who had previously undergone tumor testing to screen for Lynch Syndrome. Patients were tested for mutations in 25 cancer genes using the myRisk Hereditary Cancer test (Myriad Genetics; Salt Lake City, UT, USA).

The results showed that 9.2% of endometrial cancer patients had a deleterious mutation, including 5.8% with a mutation in a Lynch Syndrome gene and 3.4% in 10 non-Lynch genes. Multi-gene panel testing with myRisk demonstrated the ability to identify 60% more mutations, several of which are associated with ovarian and uterine cancers. These findings support gene panel testing to identify patients who may be missed by current Lynch Syndrome testing alone.

In another study, from the same institution compared the predictive ability of the combined three biomarker myChoice homologous recombination deficiency (HRD) score to the three independent measures of homologous recombination deficiency that comprise the assay including: loss of heterozygosity (LOH) score, telomeric-allelic imbalance (TAI) score, and large-scale state transitions (LST) score. The results showed that the combined myChoice HRD score predicted progression-free survival and overall survival in patients with platinum-treated ovarian cancer. In a bivariate analysis none of the individual biomarkers (LOH, TAI, and LST) reached statistical significance for either progression free survival or overall survival. In this study, myChoice HRD was shown to be a superior predictor of clinical outcomes to any of the individual score components including LOH, TAI and LST.

Johnathan Lancaster, MD, PhD, chief medical officer, at Myriad Genetic Laboratories, said, “Endometrial cancer is the most frequent gynecologic cancer and a significant number of these cases are due to mutations in hereditary cancer genes. Our new data show that gene panel testing can identify many more patients with harmful mutations than testing Lynch Syndrome genes alone. The additional information provided by the myRisk Hereditary Cancer test will help physicians optimize care for their patients.” The studies were presents at the Society for Gynecologic Oncology annual meeting, held March 19–22, 2016, in San Diego (CA, USA).

Related Links:

MD Anderson Cancer Center 
Myriad Genetics 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more